Cardiac Sympathetic Denervation in Channelopathies

Area of Science:

• Cardiology
• Electrophysiology
• Surgical Interventions

Background:

• Left cardiac sympathetic denervation (LCSD) is a surgical antiadrenergic intervention with established antiarrhythmic effects.
• Its efficacy extends beyond acute catecholamine antagonism, particularly in hearts with increased arrhythmic susceptibility like channelopathies.
• LCSD has a long-standing history of demonstrating anti-fibrillatory action, supporting its use in conditions prone to ventricular fibrillation.

Purpose of the Study:

• To review the rationale, results, and clinical approach to LCSD.
• To focus on the application of LCSD in patients with channelopathies, specifically long QT syndrome and catecholaminergic polymorphic ventricular tachycardia.
• To explore the broader molecular mechanisms underlying LCSD's antiarrhythmic effects.

Main Methods:

• Review of preclinical and clinical data on LCSD.
• Analysis of proposed molecular mechanisms including vagotonic effects, neuronal remodeling antagonism, neuropeptide Y antagonism, and nNOS imbalance correction.
• Focus on clinical outcomes and patient satisfaction in channelopathy patients.

Main Results:

• LCSD demonstrates a strong antiarrhythmic and anti-fibrillatory effect.
• Mechanisms involve more than acute catecholamine antagonism, including vagal effects and modulation of neuronal pathways.
• No detectable deterioration in cardiac performance has been associated with LCSD.
• High patient satisfaction rates are reported.

Conclusions:

• LCSD is a safe and effective antiarrhythmic intervention with multifaceted mechanisms of action.
• It provides significant benefits for patients with channelopathies, reducing ventricular fibrillation risk.
• The procedure is well-tolerated and associated with high patient satisfaction.